Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Schermuly, RT; Pullamsetti, SS; Kwapiszewska, G; Dumitrascu, R; Tian, X; Weissmann, N; Ghofrani, HA; Kaulen, C; Dunkern, T; Schudt, C; Voswinckel, R; Zhou, J; Samidurai, A; Klepetko, W; Paddenberg, R; Kummer, W; Seeger, W; Grimminger, F.
Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy.
Circulation. 2007; 115(17): 2331-2339.
Doi: 10.1161/CIRCULATIONAHA.106.676809
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Kwapiszewska-Marsh Grazyna
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Pulmonary arterial hypertension (PAH) is a life-threatening disease, characterized by vascular smooth muscle cell hyperproliferation. The calcium/calmodulin-dependent phosphodiesterase 1 (PDE1) may play a major role in vascular smooth muscle cell proliferation. METHODS AND RESULTS: We investigated the expression of PDE1 in explanted lungs from idiopathic PAH patients and animal models of PAH and undertook therapeutic intervention studies in the animal models. Strong upregulation of PDE1C in pulmonary arterial vessels in the idiopathic PAH lungs compared with healthy donor lungs was noted on the mRNA level by laser-assisted vessel microdissection and on the protein level by immunohistochemistry. In chronically hypoxic mouse lungs and lungs from monocrotaline-injected rats, PDE1A upregulation was detected in the structurally remodeled arterial muscular layer. Long-term infusion of the PDE1 inhibitor 8-methoxymethyl 3-isobutyl-1-methylxanthine in hypoxic mice and monocrotaline-injected rats with fully established pulmonary hypertension reversed the pulmonary artery pressure elevation, structural remodeling of the lung vasculature (nonmuscularized versus partially muscularized versus fully muscularized small pulmonary arteries), and right heart hypertrophy. CONCLUSIONS: Strong upregulation of the PDE1 family in pulmonary artery smooth muscle cells is noted in human idiopathic PAH lungs and lungs from animal models of PAH. Inhibition of PDE1 reverses structural lung vascular remodeling and right heart hypertrophy in 2 animal models. The PDE1 family may thus offer a new target for therapeutic intervention in pulmonary hypertension.
- Find related publications in this database (using NLM MeSH Indexing)
- 1-Methyl-3-isobutylxanthine - pharmacology
- 3',5'-Cyclic-GMP Phosphodiesterases - metabolism
- Animals -
- Cell Division -
- Chronic Disease -
- Cyclic Nucleotide Phosphodiesterases, Type 1 -
- Cyclic Nucleotide Phosphodiesterases, Type 5 -
- DNA - biosynthesis
- Disease Models, Animal -
- Humans -
- Hypertension, Pulmonary - metabolism Hypertension, Pulmonary - therapy
- Hypertrophy, Right Ventricular - metabolism Hypertrophy, Right Ventricular - therapy
- Mice -
- Muscle, Smooth, Vascular - cytology Muscle, Smooth, Vascular - enzymology
- Phosphodiesterase Inhibitors - pharmacology
- Phosphoric Diester Hydrolases - metabolism
- Pulmonary Artery - cytology Pulmonary Artery - enzymology
- Rats -
- Up-Regulation - physiology
- Find related publications in this database (Keywords)
- cardiovascular diseases
- hypertension, pulmonary
- muscle, smooth
- phosphodiesterases
- pharmacology